Meeting of the Advisory Council on Alzheimer's Research, Care, and Services, 796-797 [2012-30]
Download as PDF
<![CDATA[
796
Federal Register / Vol. 77, No. 4 / Friday, January 6, 2012 / Notices
Family Control Group, Rosemont,
Illinois, and acquire voting shares of
Taylor Capital Group, Inc., Rosemont,
Illinois, and thereby indirectly acquire
voting shares of Cole Taylor Bank,
Chicago, Illinois.
Board of Governors of the Federal Reserve
System, January 3, 2012.
Robert deV. Frierson,
Deputy Secretary of the Board.
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. Teton Financial Services, LLC,
Wilson, Wyoming; to become a bank
holding company by acquiring 100
percent of the voting shares of Rocky
Mountain Bank, Wilson, Wyoming.
[FR Doc. 2012–71 Filed 1–5–12; 8:45 am]
Board of Governors of the Federal Reserve
System, January 3, 2012.
Robert deV. Frierson,
Deputy Secretary of the Board.
BILLING CODE 6210–01–P
[FR Doc. 2012–69 Filed 1–5–12; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RESERVE SYSTEM
pmangrum on DSK3VPTVN1PROD with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than February 2,
2012.
A. Federal Reserve Bank of Cleveland
(Nadine Wallman, Vice President) 1455
East Sixth Street, Cleveland, Ohio
44101–2566:
1. KeyCorp, Cleveland, Ohio; to retain,
in a fiduciary capacity, 9.75 percent of
the outstanding voting shares of
Mechanics Financial Corporation, and
thereby retain Mechanics Savings Bank,
both in Mansfield, Ohio.
B. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
Meeting of the Advisory Council on
Alzheimer’s Research, Care, and
Services
VerDate Mar<15>2010
14:40 Jan 05, 2012
Jkt 226001
Assistant Secretary for
Planning and Evaluation, HHS.
ACTION: Notice of meeting.
AGENCY:
This notice announces public
meeting of the Advisory Council on
Alzheimer’s Research, Care, and
Services (Advisory Council). Notice of
these meetings is given under the
Federal Advisory Committee Act (5
U.S.C. App. 2, section 10(a)(1) and
(a)(2)). The Advisory Council on
Alzheimer’s Research, Care, and
Services will provide advice on how to
prevent or reduce the burden of
Alzheimer’s disease and related
dementias on people with the disease
and their caregivers. A representative
from the Department of Health and
Human Services (HHS) will present an
overview of the Draft National Plan to
Address Alzheimer’s Disease. The
chairs of the three subcommittees
(Research, Clinical Care, Long-Term
Services and Supports) will summarize
the feedback from their subcommittees
and suggest recommendations for
discussion among the full Advisory
Council. The Advisory Council will
discuss and, as appropriate, vote upon
recommendations to the Secretary of
HHS on the Draft National Plan to
Address Alzheimer’s Disease.
DATES: January 17, 2012 from 9:30 a.m.
to 4 p.m. and January 18, 2012 from 9
a.m. to 2 p.m.
ADDRESSES: The meeting will be held at
the U.S. Department of Health and
Human Services, 200 Independence
Avenue SW., Room 800, Washington,
DC 20201.
Comments: Time is allocated on the
agenda to hear public comments. In lieu
of oral comments, formal written
comments may be submitted for the
record to Helen Lamont, OASPE, 200
SUMMARY:
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
Independence Avenue SW., Room 424E,
Washington, DC 20201. Comments may
also be sent to napa@hhs.gov. Those
submitting written comments should
identify themselves and any relevant
organizational affiliations.
FOR FURTHER INFORMATION CONTACT:
Helen Lamont (202) 690–7996,
helen.lamont@hhs.gov. NOTE: Seating
may be limited. Those wishing to attend
the meeting must call or email Dr.
Lamont by Tuesday, January 10, 2012,
so that their names may be put on a list
of expected attendees and forwarded to
the security officers at the Department
of Health and Human Services. Any
interested member of the public who is
a non-U.S. citizen should include this
information at the time of registration to
ensure that the appropriate security
procedure to gain entry to the building
is carried out. Although the meeting is
open to the public, procedures
governing security and the entrance to
Federal buildings may change without
notice.
Topics of
the Meeting: The Advisory Council will
discuss the Draft National Plan to
Address Alzheimer’s Disease. The
Advisory Council is specifically charged
with making recommendations to the
Secretary on priorities for the National
Plan. As appropriate, the Advisory
Council will make, discuss, and vote on
such recommendations.
Procedure and Agenda: This meeting
is open to the public. A representative
from the Department of Health and
Human Services (HHS) will present an
overview of the Draft National Plan to
Address Alzheimer’s Disease. The
chairs of the three subcommittees
(Research, Clinical Care, Long-Term
Services and Supports) will summarize
the feedback from their subcommittees
and suggest recommendations for
discussion among the full Advisory
Council. The Advisory Council will
discuss and, as appropriate, vote upon
recommendations to the Secretary of
HHS on the Draft National Plan to
Address Alzheimer’s Disease. The
Advisory Council will also discuss how
to engage stakeholders outside of the
Federal government in the writing and
implementation of the National Plan.
The Advisory Council will allow an
open public session for any attendee to
address issues or topics that should be
addressed in the National Plan.
SUPPLEMENTARY INFORMATION:
Authority: 42 U.S.C. 11225; Section 2(e)(3)
of the National Alzheimer’s Project Act. The
panel is governed by provisions of Public
Law 92–463, as amended (5 U.S.C. Appendix
2), which sets forth standards for the
formation and use of advisory committees.
E:\FR\FM\06JAN1.SGM
06JAN1
Federal Register / Vol. 77, No. 4 / Friday, January 6, 2012 / Notices
Dated: December 19, 2011.
Sherry Glied,
Assistant Secretary for Planning and
Evaluation.
[FR Doc. 2012–30 Filed 1–5–12; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
pmangrum on DSK3VPTVN1PROD with NOTICES
National Institutes of Health Statement
of Organization, Functions, and
Delegations of Authority
Part N, National Institutes of Health
(NIH), of the Statement of Organization,
Functions, and Delegations of Authority
for the Department of Health and
Human Services (40 FR 22859, May 27,
1975, as amended most recently at 66
FR 6617, January 22, 2001, and
redesignated from Part HN as Part N at
60 FR 56605, November 9, 1995), is
amended as set forth below to establish
the National Center for Advancing
Translational Science (NCATS), to
abolish the National Center for Research
Review (NCRR), and to establish
organizational components within
National Institute of General Medical
Sciences (NIGMS), National Institute on
Minority Health and Health Disparities
(NIMHD) and the NIH Office of the
Director (OD).
Section N–8, Organization and
Functions, is amended as follows:
Immediately after the paragraph headed
‘‘Division of Program Coordination and
Integration’’ (N 875, formerly HN 875),
insert the following:
National Center for Advancing
Translational Sciences (NCATS) (N 9,
formerly HN 9) (1) Provides leadership
for a national program to advance the
discipline of translational science and
catalyze the generation of innovative
methods and technologies that will
enhance the development, testing, and
implementation of diagnostics and
therapeutics across a wide range of
human diseases and conditions; (2)
conducts intramural research; (3)
supports and coordinates research
projects through research grants,
contracts, and other mechanisms; (4)
supports training in translational
sciences; (5) collaborates with
organizations and other institutions
engaged in translational research and
training activities; and (6) collects and
disseminates research findings and
related information.
Office of the Director (OD) (N 91,
formerly HN 91) (1) Develops and
provides leadership for the Center’s
translational science programs; (2)
manages and directs executive-level
activities and functions; (3) provides
VerDate Mar<15>2010
14:40 Jan 05, 2012
Jkt 226001
policy guidance and overall operational
coordination for the organizational units
within NCATS; and (4) manages critical
points of contact and related
information flows to respond to external
inquiries.
Division of Pre-Clinical Innovation
(DPI) (N 92, formerly HN 92) (1) Plans,
conducts, and supports research across
the pre-clinical phases of the
translational science spectrum; (2)
plans, conducts, and supports research
to develop new methods and
technologies to enhance pre-clinical
processes; (3) plans, conducts, and
supports research to evaluate existing
and developing approaches,
technologies, and processes in the preclinical spectrum; (4) supports training
programs relevant to pre-clinical phases
of translational science; (5) allocates
resources to pre-clinical extramural and
intramural investigators; (6) collaborates
with ICs and the scientists they support;
and (7) consults with stakeholders,
including patients, industry, and
regulators.
Division of Clinical Innovation (DCI)
(N 93, formerly HN 93) (1) Plans,
conducts, and supports research across
the clinical phases of the translational
science spectrum; (2) plans, conducts,
and supports research to develop new
methods and technologies to enhance
clinical processes; (3) plans, conducts,
and supports research to evaluate
existing and developing approaches,
technologies, and processes in the
clinical spectrum; (4) supports training
programs relevant to clinical phases of
translational science; (5) allocates
resources to clinical extramural and
intramural investigators; (6) collaborates
with ICs and the scientists they support;
and (7) consults with stakeholders,
including patients, industry, and
regulators.
Executive Office (EO) (N 912,
formerly HN 912) (1) Directs the
administrative management and
financial management operations of
NCATS; (2) develops, administers, and
directs NCATS’ internal control
processes; (3) oversees development of
and administers NCATS policies and
procedures for administrative, program
management, and information
technology activities; and (4) oversees
personnel management and workforce
planning.
Office of Grants Management and
Scientific Review (OGMSR) (N 913,
formerly, HN 913) (1) Provides advice
and assistance to the Director of
NCATS, NCATS Division Directors, and
other NCATS officials on issues related
to policy and procedures for extramural
activities; (2) provides oversight and
direction for scientific review and grants
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
797
management activities of NCATS; (3)
coordinates NCATS small business
research programs and other special
grants programs; (4) manages the
operations of the national advisory
council for NCATS; and (5) provides
coordination, support, and staff services
for committee management.
Office of Rare Diseases Research
(ORDR) (N 914, formerly, HN 914) (1)
Guides and coordinates NIH-wide
activities involving research into
combating and treating the broad array
of rare (orphan) diseases; (2) manages
the NIH Rare Diseases and Orphan
Products Coordinating Committee
(Trans-NIH Rare Diseases Working
Group); (3) develops and maintains a
centralized database on rare diseases; (4)
coordinates and provides liaison with
Federal and non-Federal national and
international organizations concerned
with rare disease research and orphan
products development; (5) advises the
OD/NIH on matters relating to NIHsponsored research activities that
involve rare diseases and conditions;
and (6) responds to requests for
information on highly technical matters
and matters of public policy relative to
rare diseases and orphan products.
Office of Policy, Communications,
and Strategic Alliances (OPCSA) (N 915,
formerly, HN 915) (1) Provides
leadership and direction to the
planning, coordinating, reporting,
analytical, evaluative, and legislative
functions that support NCATS program
development, science policy
formulation, and overall program
direction and decision-making activities
of the NCATS executive staff; (2)
advises the NCATS Director on policy
matters pertaining to NCATS scientific
programs; (3) communicates
information about NCATS programs and
accomplishments to a wide range of
audiences; (4) advises the NCATS
Director on effective communications
strategies; (5) fosters relationships and
partnerships with stakeholders; (6)
assists in the development of content for
internal and external Web sites and
audiences; (7) develops and executes a
strategy for education and training for
the disciplines that constitute
translational science; (8) facilitates and
supports partnerships with NIH OD,
other ICs, patient groups, other
governmental agencies, nonprofits and
the private sector to achieve the goals of
the Center; and (9) oversees and
manages NCATS technology transfer
activities including overseeing NCATS
intellectual property, patent, and
licensing agreement portfolios.
Section N–D, Organization and
Functions, is amended as follows:
Immediately after the paragraph headed
E:\FR\FM\06JAN1.SGM
06JAN1
]]>Agencies
[Federal Register Volume 77, Number 4 (Friday, January 6, 2012)]
[Notices]
[Pages 796-797]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-30]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Council on Alzheimer's Research, Care,
and Services
AGENCY: Assistant Secretary for Planning and Evaluation, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: This notice announces public meeting of the Advisory Council
on Alzheimer's Research, Care, and Services (Advisory Council). Notice
of these meetings is given under the Federal Advisory Committee Act (5
U.S.C. App. 2, section 10(a)(1) and (a)(2)). The Advisory Council on
Alzheimer's Research, Care, and Services will provide advice on how to
prevent or reduce the burden of Alzheimer's disease and related
dementias on people with the disease and their caregivers. A
representative from the Department of Health and Human Services (HHS)
will present an overview of the Draft National Plan to Address
Alzheimer's Disease. The chairs of the three subcommittees (Research,
Clinical Care, Long-Term Services and Supports) will summarize the
feedback from their subcommittees and suggest recommendations for
discussion among the full Advisory Council. The Advisory Council will
discuss and, as appropriate, vote upon recommendations to the Secretary
of HHS on the Draft National Plan to Address Alzheimer's Disease.
DATES: January 17, 2012 from 9:30 a.m. to 4 p.m. and January 18, 2012
from 9 a.m. to 2 p.m.
ADDRESSES: The meeting will be held at the U.S. Department of Health
and Human Services, 200 Independence Avenue SW., Room 800, Washington,
DC 20201.
Comments: Time is allocated on the agenda to hear public comments.
In lieu of oral comments, formal written comments may be submitted for
the record to Helen Lamont, OASPE, 200 Independence Avenue SW., Room
424E, Washington, DC 20201. Comments may also be sent to napa@hhs.gov.
Those submitting written comments should identify themselves and any
relevant organizational affiliations.
FOR FURTHER INFORMATION CONTACT: Helen Lamont (202) 690-7996,
helen.lamont@hhs.gov. NOTE: Seating may be limited. Those wishing to
attend the meeting must call or email Dr. Lamont by Tuesday, January
10, 2012, so that their names may be put on a list of expected
attendees and forwarded to the security officers at the Department of
Health and Human Services. Any interested member of the public who is a
non-U.S. citizen should include this information at the time of
registration to ensure that the appropriate security procedure to gain
entry to the building is carried out. Although the meeting is open to
the public, procedures governing security and the entrance to Federal
buildings may change without notice.
SUPPLEMENTARY INFORMATION: Topics of the Meeting: The Advisory Council
will discuss the Draft National Plan to Address Alzheimer's Disease.
The Advisory Council is specifically charged with making
recommendations to the Secretary on priorities for the National Plan.
As appropriate, the Advisory Council will make, discuss, and vote on
such recommendations.
Procedure and Agenda: This meeting is open to the public. A
representative from the Department of Health and Human Services (HHS)
will present an overview of the Draft National Plan to Address
Alzheimer's Disease. The chairs of the three subcommittees (Research,
Clinical Care, Long-Term Services and Supports) will summarize the
feedback from their subcommittees and suggest recommendations for
discussion among the full Advisory Council. The Advisory Council will
discuss and, as appropriate, vote upon recommendations to the Secretary
of HHS on the Draft National Plan to Address Alzheimer's Disease. The
Advisory Council will also discuss how to engage stakeholders outside
of the Federal government in the writing and implementation of the
National Plan. The Advisory Council will allow an open public session
for any attendee to address issues or topics that should be addressed
in the National Plan.
Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National
Alzheimer's Project Act. The panel is governed by provisions of
Public Law 92-463, as amended (5 U.S.C. Appendix 2), which sets
forth standards for the formation and use of advisory committees.
[[Page 797]]
Dated: December 19, 2011.
Sherry Glied,
Assistant Secretary for Planning and Evaluation.
[FR Doc. 2012-30 Filed 1-5-12; 8:45 am]
BILLING CODE P
